Anti-SLC34A2 (Lifastuzumab) -MC-Vc-PAB-SN38
Anti-SLC34A2 (Lifastuzumab) -MC-Vc-PAB-SN38 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab conjugated to the linker Mc-VC-PAB and the topoisomerase I inhibitor SN38 (HY-13704). The ADC toxic molecule and linker part are Mc-VC-PAB-SN38 (HY-131057). Anti-SLC34A2 (Lifastuzumab) -MC-Vc-PAB-SN38 can be used in cancer research[1][2].
Product Specifications
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Sodium Channel; Topoisomerase
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[Anti-SLC34A2(Lifastuzumab)-MC-Vc-PAB-SN38]
References & Citations
Shipping Conditions
Room temperature
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
Topo I
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TAG-72 / CA72.4 (B72.3), CF568 conjugate, 0.1mg/mL
MUC18 / Mucin 18 / CD146 (OJ79c), CF568 conjugate, 0.1mg/mL
TGF-beta (1D11.16.8), CF594 conjugate, 0.1mg/mL
